Jump to content

Early Phase Studies w/Sorafenib

Recommended Posts

http://www.prnewswire.com/cgi-bin/stori ... 252&EDATE=

Excerpt from PRNewsWire-FirstCall:

. . . . . . . . .

New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting

(Nasdaq: ONXX) today announced the presentation of new clinical data from the early clinical trials in the development program for Nexavar®(sorafenib) tablets in multiple tumor types including lung, thyroid, gastric and ovarian cancers. Nexavar is currently approved in more than 40 countries for the treatment of patients with unresectable liver cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer.

"Findings from these early phase studies are encouraging and will be integral in informing our development strategies for the ongoing Nexavar clinical program," said Henry Fuchs, MD, executive vice president and chief medical officer of Onyx Pharmaceuticals. "We are committed to maximizing

the potential of Nexavar and look forward to its ongoing study with international study groups, government agencies and individual investigators in a wide range of cancers."

Highlights from Nexavar data presented include:

Lung Cancer

A Randomized, Discontinuation Phase 2 Study of Sorafenib vs. Placebo in Patients with Non-Small Cell Lung Cancer (NSCLC) Who Have Failed at Least Two Prior Chemotherapy Regimens

Preliminary findings from this randomized discontinuation Phase 2 study showed that treatment with Nexavar yielded encouraging results in heavily pre-treated patients with NSCLC. The study showed that patients who remained on Nexavar experienced a longer period of disease control and disease stabilization than patients who discontinued Nexavar after the initial run-in phase of treatment. In the study, the most common treatment-emergent adverse events included fatigue, hand/foot syndrome and skin rash.

The lead investigator for this study is Joan Schiller, MD, professor and chief of the hematology/oncology division at the University of Texas Southwestern and Andrea L. Simmons distinguished chair in cancer research, Dallas, TX. (abstract #8014).

. . . . . . . . .

(PRNewsWire-FirstCall, Source: Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals, June 2, 2008 [Contains Forward-looking Statements])


The information contained in these articles may or may not be in agreement with my own opinions. They are not posted as medical advice of any kind.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.